Headquarters


Grünenthal Group
Zieglerstraße 6
52078 Aachen
Germany

Phone: +49 241 569-0
(24h availability for medical emergencies)

Contact Form

Adverse Drug Reaction Reporting

 

 

Global Financial Services

Requests concerning your invoices

- 00800 478 363 68 for local language

- 00800 478 363 69 for English

 

Innovating at Scale: Gabriel Baertschi Interview Economist Intelligence Unit


In an interview with the Economist Intelligence Unit our CEO talks about Grünenthal’s ambition, explains why it is necessary to go for a network based approach in R&D and what his concept of leadership is all about.

Grünenthal Clinical Trial Portal

Grünenthal Group

The Grünenthal Group

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.

Read more...

Distribution agreement with MSD

Grünenthal to distribute, promote, and sell MSD’s Women’s Health products in several countries in Latin America

Aachen, January 23, 2018 – Grünenthal announced today that it has entered into a distribution agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for distributing, promoting and selling MSD’s Women’s Health products in Brazil, Central America, Colombia, Mexico and Peru. The portfolio comprises several Women’s Health products, including Zoely®, Nuvaring®, Cerazette® and Livial®. MSD will continue to commercialize Nexplanon®/Implanon NXT® throughout that region.

Read more...